SML0650
Risedronate sodium
≥97% (HPLC)
别名:
P,P′-[1-Hydroxy-2-(3-pyridinyl)ethylidene]bis-phosphonic acid sodium, Sodium risedronate, [1-Hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Quality Level
assay
≥97% (HPLC)
form
powder
color
white to beige
solubility
H2O: 5 mg/mL, clear (warmed)
storage temp.
room temp
SMILES string
[Na+].[P](=O)([O-])(O)[C@]([P](=O)(O)O)(O)Cc1cnccc1
InChI
1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1
InChI key
DRFDPXKCEWYIAW-UHFFFAOYSA-M
Biochem/physiol Actions
Risedronate sodium is a bisphosphonate bone resorption inhibitor.
Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Antonio Casado-Díaz et al.
Archives of medical research, 44(5), 325-334 (2013-07-23)
Bisphosphonates are widely used for the treatment of bone pathologies, mainly due to their ability to inhibit osteoclastic activity and thus bone resorption. Yet, their potential effect on bone formation is unclear. Our aim was to determine whether risedronate can
R Lindsay et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 24(8), 2345-2352 (2013-04-25)
This observational study showed that after 2 years, both risedronate and alendronate lowered the risk of hip and nonvertebral fractures compared with patients filling in a single bisphosphonate prescription. Post hoc analyses of the placebo-controlled trials suggested earlier effects for
J S Thomsen et al.
Scandinavian journal of rheumatology, 42(5), 408-416 (2013-03-27)
To investigate whether treatment with a bisphosphonate would influence the subchondral bone plate stiffness and the development of cartilage damage in Dunkin Hartley guinea pigs, which develop osteoarthritis (OA) spontaneously. Fifty-six 3-month-old male Dunkin Hartley guinea pigs were randomized into
Job F M van Boven et al.
Journal of bone and mineral metabolism, 31(5), 562-570 (2013-04-12)
Low persistence with osteoporosis medication is associated with higher fracture risk. Previous studies estimated that 1-year persistence with osteoporosis medication is low. Our aim was to study persistence with osteoporosis medication among patients with long-term follow-up (to 5 years). The InterAction
Irit Ben-Aharon et al.
PloS one, 8(8), e70044-e70044 (2013-08-31)
The role of bisphosphonates (BP) in early breast cancer (BC) has been considered controversial. We performed a meta-analysis of all randomized controlled trials (RCTs) that appraised the effects of BP on survival in early BC. RCTs were identified by searching
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0650-50MG | 04061837101205 |
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持